Validation of a metabolite panel for early diagnosis of type 2 diabetes

详细信息    查看全文

• 作者：Tonia C. Carter^a ; ^{carter.tonia@mcrf.mfldclin.edu" class="auth_mail" title="E-mail the corresponding author} ; Dietrich Rein^b ; ^{dietrich.rein@metanomics-health.de" class="auth_mail" title="E-mail the corresponding author} ; Inken Padberg^c ; ^{inken.padberg@charite.de" class="auth_mail" title="E-mail the corresponding author} ; Erik Peter^d ; ^{erik.peter@metanomics.de" class="auth_mail" title="E-mail the corresponding author} ; Ulrike Rennefahrt^d ; ^{ulrike.rennefahrt@metanomics.de" class="auth_mail" title="E-mail the corresponding author} ; Donna E. David^e ; ^{david.donna@mcrf.mfldclin.edu" class="auth_mail" title="E-mail the corresponding author} ; Valerie McManus^f ; ^{valeriedmcmanus@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Elisha Stefanski^e ; ^{stefanski.elisha@mcrf.mfldclin.edu" class="auth_mail" title="E-mail the corresponding author} ; Silke Martin^g ; ^{s.martin@blutspendedienst.com" class="auth_mail" title="E-mail the corresponding author} ; Philipp Schatz^b ; ^{philipp.schatz@metanomics-health.de" class="auth_mail" title="E-mail the corresponding author} ; Steven J. Schrodi^a ; ^{schrodi.steven@mcrf.mfldclin.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Biomarker ; Diabetes ; Metabolomics ; Glucose ; Predictive modeling
• 刊名：Metabolism
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：65
• 期：9
• 页码：1399-1408
• 全文大小：465 K

文摘

Accurate, early diagnosis of type 2 diabetes (T2D) would enable more effective clinical management and a reduction in T2D complications. Therefore, we sought to identify plasma metabolite and protein biomarkers that, in combination with glucose, can better predict future T2D compared with glucose alone.

Methods

In this case–control study, we used plasma samples from the Bavarian Red Cross Blood Transfusion Center study (61 T2D cases and 78 non-diabetic controls) for discovering T2D-associated metabolites, and plasma samples from the Personalized Medicine Research Project in Wisconsin (56 T2D cases and 445 non-diabetic controls) for validation. All samples were obtained before or at T2D diagnosis. We tested whether the T2D-associated metabolites could distinguish incident T2D cases from controls, as measured by the area under the receiver operating characteristic curve (AUC). Additionally, we tested six metabolic/pro-inflammatory proteins for their potential to augment the ability of the metabolites to distinguish cases from controls.

Results

A panel of 10 metabolites discriminated better between T2D cases and controls than glucose alone (AUCs: 0.90 vs 0.87; p = 2.08 × 10^− 5) in Bavarian samples, and associations between these metabolites and T2D were confirmed in Wisconsin samples. With use of either a Bayesian network classifier or ridge logistic regression, the metabolites, with or without the proteins, discriminated incident T2D cases from controls marginally better than glucose in the Wisconsin samples, although the difference in AUCs was not statistically significant. However, when the metabolites and proteins were added to two previously reported T2D prediction models, the AUCs were higher than those of each prediction model alone (AUCs: 0.92 vs 0.87; p = 3.96 × 10^− 2 and AUCs: 0.91 vs 0.71; p = 1.03 × 10^− 5, for each model, respectively).

Conclusions

Compared with glucose alone or with previously described T2D prediction models, a panel of plasma biomarkers showed promise for improved discrimination of incident T2D, but more investigation is needed to develop an early diagnostic marker.